Akebia Therapeutics files Form 144 for RSU vesting

Akebia Therapeutics submitted a Form 144 notice related to Common Stock tied to the vesting of restricted stock units on 06/28/2026.

Rhea-AI Filing Summary

Akebia Therapeutics submitted a Form 144 notice related to Common Stock tied to the vesting of restricted stock units on 06/28/2026. The filing lists 56,019 in connection with the equity compensation event and references Nasdaq and the date 06/29/2026.

Key Figures

Listed quantity: 56,019 Reported date (vesting): 06/28/2026 Reported date (filing/exchange line): 06/29/2026 +2 more

5 metrics

Listed quantity 56,019 appears next to Common Stock and equity compensation

Reported date (vesting) 06/28/2026 Vesting of restricted stock unit

Reported date (filing/exchange line) 06/29/2026 Date shown alongside Nasdaq and security information

Identifier number 268258243 numeric value listed in the excerpt (label not specified)

Additional numeric field 62220.00 numeric entry present in the securities information row

Key Terms

restricted stock unit, Form 144, equity compensation

3 terms

restricted stock unit financial

"Vesting of restricted stock unit"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

Form 144 regulatory

"submitted a Form 144 notice related to Common Stock"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

equity compensation financial

"equity compensation"

Equity compensation is pay given to employees, executives or contractors in the form of company ownership—such as stock, stock options or restricted shares—rather than just cash. It matters to investors because it can align workers' incentives with shareholders (like paying someone in slices of the same pie they help grow), but it also increases the number of shares outstanding and company expenses, affecting ownership percentages and earnings per share.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Akebia Therapeutics' Form 144 (AKBA) report?

It reports a Form 144 notice for Common Stock tied to RSU vesting. The filing references the vesting date 06/28/2026 and lists 56,019 alongside Nasdaq and the filing date 06/29/2026.

How many shares are identified in the Form 144 filing for AKBA?

The filing lists 56,019 as the relevant figure. That number appears next to the Common Stock and equity compensation entries in the excerpt provided, with dates 06/28/2026 and 06/29/2026.

What transaction trigger is stated in the AKBA excerpt?

The transaction trigger is the vesting of restricted stock units. The excerpt explicitly states "Vesting of restricted stock unit" with the vesting date shown as 06/28/2026.

Does the excerpt state whether proceeds go to the issuer or selling holder for AKBA?

Cash‑flow treatment is not described in the excerpt. The provided lines list security, vesting, and numeric identifiers but do not state who receives proceeds or how any shares will be sold.

Which exchange is referenced in the Form 144 excerpt for AKBA?

The excerpt references Nasdaq. The exchange label appears alongside the security information and the date 06/29/2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/29/2026 - 08:38 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001762507
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Akebia Therapeutics, Inc.
SEC File Number	001-36352
Address of Issuer	245 FIRST STREET CAMBRIDGE MASSACHUSETTS 02142
Phone	617-871-2098
Name of Person for Whose Account the Securities are To Be Sold	Ostrowski Erik
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC 1 New York Plaza, 38th Floor New York NY 10004	56019	62220.00	268258243	06/29/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	06/28/2026	Vesting of restricted stock unit	Akebia Therapeutics, Inc.			56019	06/29/2026	equity compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	06/29/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Carolyn M. Rucci, attorney-in-fact for Erik Ostrowski
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)